Tower Research Capital LLC (Trc) Crinetics Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

$3.68 Billion
Q3 2024

A detailed history of Tower Research Capital LLC (Trc) transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 452 shares of CRNX stock, worth $24,227. This represents 0.0% of its overall portfolio holdings.

Number of Shares

452

Previous 12,856 96.48%

Holding current value

$24,227

Previous $575,000 96.0%

% of portfolio

0.0%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$43.83 - $54.98 $543,667 - $681,971	-12,404 Reduced 96.48%	452 $23,000
Q2 2024 Aug 13, 2024	BUY	$42.12 - $51.91 $517,275 - $637,506	12,281 Added 2135.83%	12,856 $575,000
Q1 2024 May 15, 2024	SELL	$34.76 - $46.81 $105,253 - $141,740	-3,028 Reduced 84.04%	575 $26,000
Q4 2023 Feb 13, 2024	BUY	$25.62 - $37.07 $52,239 - $75,585	2,039 Added 130.37%	3,603 $128,000
Q3 2023 Nov 14, 2023	SELL	$15.97 - $30.59 $47,590 - $91,158	-2,980 Reduced 65.58%	1,564 $46,000
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $41,165 - $61,761	2,617 Added 135.81%	4,544 $81,000
Q1 2023 May 09, 2023	BUY	$15.31 - $21.1 $15,447 - $21,289	1,009 Added 109.91%	1,927 $31,000
Q4 2022 Feb 10, 2023	SELL	$15.49 - $19.05 $143,607 - $176,612	-9,271 Reduced 90.99%	918 $17,000
Q3 2022 Nov 10, 2022	BUY	$18.11 - $22.37 $102,991 - $127,218	5,687 Added 126.32%	10,189 $200,000
Q2 2022 Aug 15, 2022	SELL	$16.49 - $27.64 $201,870 - $338,368	-12,242 Reduced 73.11%	4,502 $84,000
Q1 2022 May 12, 2022	BUY	$17.15 - $28.31 $226,825 - $374,428	13,226 Added 375.95%	16,744 $368,000
Q4 2021 Feb 14, 2022	SELL	$19.35 - $28.41 $4,779 - $7,017	-247 Reduced 6.56%	3,518 $100,000
Q3 2021 Nov 15, 2021	BUY	$16.88 - $25.23 $31,751 - $47,457	1,881 Added 99.84%	3,765 $79,000
Q2 2021 Aug 16, 2021	BUY	$15.9 - $21.15 $19,604 - $26,077	1,233 Added 189.4%	1,884 $36,000
Q1 2021 May 17, 2021	SELL	$13.3 - $17.55 $72,112 - $95,156	-5,422 Reduced 89.28%	651 $10,000
Q4 2020 Feb 16, 2021	SELL	$12.08 - $17.46 $203,076 - $293,520	-16,811 Reduced 73.46%	6,073 $86,000
Q3 2020 Nov 16, 2020	BUY	$13.62 - $17.66 $266,706 - $345,818	19,582 Added 593.03%	22,884 $359,000
Q2 2020 Aug 13, 2020	BUY	$13.04 - $23.23 $43,058 - $76,705	3,302 New	3,302 $58,000
Q4 2019 Feb 07, 2020	SELL	$15.24 - $25.09 $41,010 - $67,517	-2,691 Closed	0 $0
Q3 2019 Nov 05, 2019	BUY	$14.91 - $25.01 $32,712 - $54,871	2,194 Added 441.45%	2,691 $40,000
Q2 2019 Aug 13, 2019	SELL	$21.48 - $27.71 $12,286 - $15,850	-572 Reduced 53.51%	497 $12,000
Q1 2019 May 14, 2019	SELL	$21.07 - $29.31 $15,570 - $21,660	-739 Reduced 40.87%	1,069 $24,000
Q4 2018 Feb 14, 2019	BUY	$22.4 - $35.39 $40,499 - $63,985	1,808 New	1,808 $54,000

Others Institutions Holding CRNX

# of Institutions

241

Shares Held

79.5M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.88B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Account

Tower Research Capital LLC (Trc) Crinetics Pharmaceuticals, Inc. Transaction History